Psychedelic stocks, like Mind Med (MNMD) could see higher highs.

All as such treatments show progress in the treatment of depression, anxiety, OCD, ADHD addiction, and post-traumatic stress disorder.

In fact, “Researchers at Johns Hopkins and NYU conducted multiple small studies of cancer patientswho experienced anxiety and depression as a result of their diagnoses. After giving these patients psilocybin, the majority reported an improvement in these symptoms immediately after treatment and over time,” reports

  • A study from JAMA Psychiatry just found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
  • New York Univ. found “Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreased in cancer-related demoralization and hopelessness, improved spiritual well-being.”
  • Even the US FDA called psilocybin a breakthrough therapy.

While the MNMD stock didn’t do so hot on its first day on the NASDAQ, give it time.  If psychedelic treatments gain traction – as expected – MNMD could easily see higher highs. Plus, if psychedelics can disrupt current treatments of anxiety, ADHD addition, and depression, MNMD could be exposed to multi-billion-dollar opportunities.

Global annual anxiety drug sales are up to $4.7 billion, according to the company’s investor deck.  Global annual ADHD sales are up to $9.5 billion.  Anti-addition drug sales are up to $5.8 billion.  Global depression drug sales are up to $9.6 billion.